| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | TBC |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487 | Technology appraisal guidance | |
| Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
| Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627 | Technology appraisal guidance | TBC |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |
| Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425] | Technology appraisal guidance | TBC |
| Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
| Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459 | Technology appraisal guidance | |
| Insulin icodec for treating type 2 diabetes [ID6175] | Technology appraisal guidance | TBC |
| Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355] | Technology appraisal guidance | TBC |
| Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
| Iptacopan for treating complement 3 glomerulopathy [ID6283] | Technology appraisal guidance | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 | Technology appraisal guidance | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Technology appraisal guidance | |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517] | Technology appraisal guidance | TBC |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
| Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305] | Technology appraisal guidance | TBC |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | |
| Lenacapavir for preventing HIV-1 in people aged 16 years or older ID6495 | Technology appraisal guidance | |
| Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance | TBC |
| Leriglitazone for treating andrenoleukodystrophy [ID3903] | Technology appraisal guidance | TBC |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166] | Technology appraisal guidance | TBC |
| Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390] | Technology appraisal guidance | TBC |
| Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Technology appraisal guidance | |
| Linzagolix for treating symptoms of endometriosis [ID6357] | Technology appraisal guidance | |
| Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174] | Technology appraisal guidance | TBC |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Technology appraisal guidance | |
| Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] | Technology appraisal guidance | TBC |
| Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
| Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] | Technology appraisal guidance | |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257] | Technology appraisal guidance | TBC |
| Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy
[ID6523] | Technology appraisal guidance | TBC |